NCT01546987 2026-03-06
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
Clinical Trials
105 trialsNCT05700903 2026-03-02
ARCH
University of Colorado, Denver
Phase 4 Completed
NCT05701007 2026-01-29
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Pfizer
Completed
NCT02772588 2026-01-27
AASUR in High Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03070886 2026-01-14
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NRG Oncology
Phase 2/3 Completed
NCT03056755 2026-01-13
BYLieve
Novartis
Phase 2 Completed
NCT05122377 2026-01-06
RWE About QOL and Compliance of Patients With OFS in China
Fudan University
Completed
NCT03007732 2025-12-05
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
University of California, San Francisco
Phase 2 Completed
NCT05605964 2025-08-17
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT03298087 2025-08-01
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
VA Office of Research and Development
Phase 2 Completed
NCT02903368 2025-06-13
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02278185 2025-05-11
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
University of Colorado, Denver
Phase 2 Completed
NCT05440383 2025-03-14
A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia
Kissei Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT03035032 2024-11-26
A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients
Astellas Pharma Inc
Phase 4 Completed
NCT02366494 2024-11-25
Micro RNAs to Predict Response to Androgen Deprivation Therapy
Medical College of Wisconsin
Completed
NCT03572387 2024-04-30
A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment
Icahn School of Medicine at Mount Sinai
Phase 2 Completed
NCT03272477 2024-04-17
TP-II
Palleos Healthcare GmbH
Phase 2 Completed
NCT00099086 2024-01-31
Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer
Medical University of South Carolina
Phase 1 Completed
NCT02543255 2024-01-31
ACDC-RP
University Health Network, Toronto
Phase 2 Completed
NCT00541047 2023-11-13
RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local Surgery
University College, London
Phase 3 Completed
NCT00587431 2023-11-07
Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02941926 2023-10-24
COMPLEEMENT-1
Novartis
Phase 3 Completed
NCT00002889 2023-08-18
Radiation Therapy With Androgen Suppression in Treating Patients With Prostate Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT04897958 2023-07-27
Prediction of the PRONOUNCE Prostate Cancer Trial in Healthcare Claims Data
Brigham and Women's Hospital
Completed
NCT03043807 2023-02-16
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01642186 2022-12-29
Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02064036 2022-10-18
CCRO025
University of California, Davis
Phase 1 Completed
NCT01989780 2022-08-04
BOOSTER
Japan Breast Cancer Research Group
Phase 2 Completed
NCT02716974 2022-08-04
oligo-mets
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02770391 2022-06-21
Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT02268175 2022-04-19
Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05304169 2022-03-31
PRIZE
Zodiac Produtos Farmaceuticos S.A.
Phase 4 Completed
NCT03085095 2022-01-18
HERO
Myovant Sciences GmbH
Phase 3 Completed
NCT00116220 2022-01-06
Study of External Beam Radiation Therapy With and Without Hormonal Therapy to Treat Prostate Cancer
Dana-Farber Cancer Institute
Phase 3 Completed
NCT00003653 2021-06-23
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT02064582 2020-10-12
Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT02059213 2020-09-16
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT02344550 2020-07-30
LEO
Asan Medical Center
Phase 2 Completed
NCT00002633 2020-04-03
Hormone Therapy With or Without Surgery or Radiation Therapy in Treating Patients With Prostate Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT01790126 2020-03-11
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 2 Completed
NCT00582556 2019-11-26
Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy
University of Wisconsin, Madison
Phase 2 Completed
NCT03209518 2019-11-01
Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer"
Takeda
Completed
NCT00254397 2019-10-16
Melanoma Vaccine With Peptides and Leuprolide
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00669162 2019-07-24
Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
University of Kansas Medical Center
Phase 1/2 Completed
NCT02085252 2019-06-28
A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
Takeda
Phase 3 Completed
NCT02057939 2019-06-26
STREAM
Duke University
Phase 2 Completed
NCT03209492 2019-04-11
Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for "Prostate Cancer"
Takeda
Completed
NCT01547299 2018-10-23
Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
Pfizer
Phase 2 Completed
NCT00223665 2018-08-07
IAS
University of Washington
Phase 2 Completed
NCT00002597 2018-06-14
Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed